Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at JPMorgan Chase & Co.

Key Points

• JPMorgan initiated coverage of Dianthus Therapeutics with an “overweight” rating and a $135 price target, implying approximately 30.7% upside. Analysts overall assign the stock a “Moderate Buy” rating with an average target of $129.83.
• Dianthus reported a quarterly loss of $0.90 per share, missing estimates by $0.05, while revenue of $0.76 million exceeded expectations. Analysts project a full-year loss of $3.83 per share.
• Insiders have been substantial sellers, disposing of 283,678 shares worth about $29.7 million during the last quarter; institutional investors own 47.53% of the company. Dianthus is developing DNTH103, an investigational antibody targeting complement-mediated diseases.

Research analysts at JPMorgan Chase & Co. initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage set an "overweight" rating and a $135.00 price target on the stock. JPMorgan Chase & Co.'s price target points to a potential upside of 30.71% from the company's current price.

A number of other brokerages have also issued reports on DNTH. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. TD Cowen reiterated a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Raymond James Financial restated a "strong-buy" rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Citigroup initiated coverage on Dianthus Therapeutics in a research report on Friday, September 4th. They issued a "buy" rating and a $156.00 target price on the stock. Finally, Wedbush increased their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Dianthus Therapeutics has an average rating of "Moderate Buy" and an average price target of $129.83.

Dianthus Therapeutics Price Performance

DNTH opened at $103.28 on Friday. The stock has a market capitalization of $5.65 billion, a P/E ratio of -24.89 and a beta of 1.24. The company's 50 day simple moving average is $106.23 and its 200-day simple moving average is $91.00. Dianthus Therapeutics has a one year low of $32.22 and a one year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. As a group, analysts anticipate that Dianthus Therapeutics will post -3.83 EPS for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, Director Anne McGeorge sold 7,750 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the transaction, the director directly owned 1,250 shares in the company, valued at approximately $136,262.50. This represents a 86.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Simrat Randhawa sold 23,124 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at $425,640. This represents a 85.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 283,678 shares of company stock worth $29,672,400. 3.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after buying an additional 618 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company's stock valued at $1,009,000 after purchasing an additional 6,323 shares in the last quarter. Invesco Ltd. grew its position in shares of Dianthus Therapeutics by 31.1% during the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company's stock worth $390,000 after buying an additional 4,962 shares during the period. Alliancebernstein L.P. increased its stake in shares of Dianthus Therapeutics by 14.5% in the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock valued at $21,887,000 after acquiring an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at $27,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company's lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.